|
July 26, 2022
| This week's startup news for biopharma leaders
Note from the editor
New medicines don’t appear out of thin air. Each are stories of people and perseverance. The big idea someone believed in and risked failure to pursue. The investors convinced it might work. And the startup companies that spend years, or even decades, trying to turn an idea into a drug that changes lives.
These stories drive the biotechnology industry and the sprawling research ecosystem that supports it. They will be the focus of this newsletter, which will run weekly on Tuesday mornings.
We’ll give you a unique look into the world of biotech startups, the people who back them and the challenges they face. You can expect a regular mix of insight, analysis, data and story formats that you won’t find anywhere else. Sound like something a colleague would enjoy? You can refer them using this link: https://www.biopharmadive.com/signup/emerging-biotech/?signup_referred_by=
We’ll have more to share in the weeks ahead. In the meantime, please send us any feedback, questions or tips. Thanks for reading BioPharma Dive!
Ben Fidler
Senior Editor, BioPharma Dive
E-mail
Deep Dive
New drug companies are being built more carefully and platform technologies are less in vogue, a sign the next group of startups could look different.
|
Three startups have recently emerged with plans to edit the epigenome rather than DNA directly. Here’s why that matters and what they aim to do.
|
UPDATED
This database is regularly updated with new biotech IPOs as they’re filed and priced, allowing you to track how startups are making the jump to public markets. The chart above is a snapshot of where things stand after Q2.
|
UPDATED
The Lilly-backed Rona Therapeutics gains rights to a platform for small interfering RNA, along with a slate of preclinical candidates aimed at targets in the liver and other tissues.
|
The cell therapy developer, which was formed in early 2017 by a group that includes Nobel Prize winner David Baltimore, is one of dozens of biotechs to cut staff this year.
|
The California biotech is exercising its option to acquire GeneTx BioTherapeutics for $75 million after seeing data from the companies’ study of an Angelman syndrome treatment.
|
The Swiss drugmaker, which already owns rights to a marketed gene therapy for inherited vision loss, will work with startup Avista Therapeutics to develop better delivery tools for the complex treatments.
|
What We're Reading
C&EN
|
BioCentury
|
Business Insider
|
Labiotech
|
Upcoming Events
Dive Into a Topic
|
